Europe Cardiac Marker Testing Market Size, Share, Trends and Overview 2021
©
Europe Cardiac Marker Testing Market Size is anticipated to grow at 8.94% CAGR from 2016 to 2021 and it is estimated that the Europe market was valued at USD 0.60 billion in 2016 and is expected to reach USD 0.92 billion by 2021.
Cardiac marker tests identify blood chemicals associated with myocardial infarction (MI), commonly known as a heart attack. The myocardium is the middle layer of the heart wall composed of heart muscle. Infarction is tissue death caused by an interruption in the blood supply to an area. Cardiac markers help physicians to assess acute coronary syndromes and to identify and manage high-risk patients. Creatine kinase-MB (CK-MB), myoglobin, homocysteine, C-reactive protein (CRP), troponin T (cTnT), and troponin I (cTnI) are all used for assessment of the suspected acute myocardial infarction. CK-MB, cTnT, and cTnI may also be used to identify and manage high-risk patients.
Full report at: http://www.marketdataforecast.com/market-reports/europe-cardiac-marker-testing-market-4985/
Factor such as increase in the incidence and occurrences of cardiovascular diseases is among the main factors driving the market growth. Furthermore, a number of factors such as growing instances of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse schemes are expected to hinder the growth of the market.
The Europe Cardiac Marker Testing Market Segmentation by Type, Product, Disease and Testing. On the basis of Type, it is segmented into Troponin I & T, CK-MB, Myoglobin, BNP, and hsCRP. The creatine kinase segment is further segmented into M & B subunits: CK-MM, CK-MB, and CK-BB. The troponin cardiac biomarkers segment held the largest share of this market segment. On the basis of Product, it is segmented into Reagent and Instrument. The instrument segment is furtherer segmented into Chemiluminescence, Immunofluorescence, Immunochromatography, and ELISA. On the basis of Disease, it is segmented into Acute Coronary Syndrome, Myocardial Infarction, and Congestive Heart Failure. ACS is expected to be the fasting growing segment driven. Myocardial infarction is anticipated to be the second fastest growing segment. On the basis of Testing, it is segmented into Lab and POC. The laboratory testing segment is expected to hold the largest share of this market segment, while the point-of-care testing segment is expected to register the highest growth rate in this market segment.
Request sample: http://www.marketdataforecast.com/market-reports/europe-cardiac-marker-testing-market-4985/request-sample
On the basis of geography, the market is analyzed under various regions namely North America, Europe, Asia-Pacific and Middle East and Africa. Europe held the second largest share of the market. Factors such as public–private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors aiding the growth of the markets.
Europe Cardiac Marker Testing Market Leaders are LSI Medience Corporation, Ortho Clinical Diagnostics,Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Cardiac marker tests identify blood chemicals associated with myocardial infarction (MI), commonly known as a heart attack. The myocardium is the middle layer of the heart wall composed of heart muscle. Infarction is tissue death caused by an interruption in the blood supply to an area. Cardiac markers help physicians to assess acute coronary syndromes and to identify and manage high-risk patients. Creatine kinase-MB (CK-MB), myoglobin, homocysteine, C-reactive protein (CRP), troponin T (cTnT), and troponin I (cTnI) are all used for assessment of the suspected acute myocardial infarction. CK-MB, cTnT, and cTnI may also be used to identify and manage high-risk patients.
Full report at: http://www.marketdataforecast.com/market-reports/europe-cardiac-marker-testing-market-4985/
Factor such as increase in the incidence and occurrences of cardiovascular diseases is among the main factors driving the market growth. Furthermore, a number of factors such as growing instances of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse schemes are expected to hinder the growth of the market.
The Europe Cardiac Marker Testing Market Segmentation by Type, Product, Disease and Testing. On the basis of Type, it is segmented into Troponin I & T, CK-MB, Myoglobin, BNP, and hsCRP. The creatine kinase segment is further segmented into M & B subunits: CK-MM, CK-MB, and CK-BB. The troponin cardiac biomarkers segment held the largest share of this market segment. On the basis of Product, it is segmented into Reagent and Instrument. The instrument segment is furtherer segmented into Chemiluminescence, Immunofluorescence, Immunochromatography, and ELISA. On the basis of Disease, it is segmented into Acute Coronary Syndrome, Myocardial Infarction, and Congestive Heart Failure. ACS is expected to be the fasting growing segment driven. Myocardial infarction is anticipated to be the second fastest growing segment. On the basis of Testing, it is segmented into Lab and POC. The laboratory testing segment is expected to hold the largest share of this market segment, while the point-of-care testing segment is expected to register the highest growth rate in this market segment.
Request sample: http://www.marketdataforecast.com/market-reports/europe-cardiac-marker-testing-market-4985/request-sample
On the basis of geography, the market is analyzed under various regions namely North America, Europe, Asia-Pacific and Middle East and Africa. Europe held the second largest share of the market. Factors such as public–private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors aiding the growth of the markets.
Europe Cardiac Marker Testing Market Leaders are LSI Medience Corporation, Ortho Clinical Diagnostics,Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases